Brief: Vaccinex Announces Expansion of Pepinemab Development Program To Alzheimer's Disease
09/03/2020 12:18
March 9 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX REPORTS FOURTH QUARTER AND FULL YEAR 2019
FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
* VACCINEX INC - ON-TRACK TO REPORT TOPLINE DATA FROM
CLASSICAL-LUNG AND SIGNAL CLINICAL TRIALS THIS YEAR
* VACCINEX INC - ANNOUNCES EXPANSION OF PEPINEMAB
DEVELOPMENT
PROGRAM INTO ALZHEIMER'S DISEASE
* VACCINEX - CASH AND CASH EQUIVALENTS AND MARKETABLE
SECURITIES
ON DECEMBER 31, 2019 WERE $2.8 MILLION
Source text for Eikon: ID:nGNXzjHZw
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease